BIOLASE Inc. Reaches The Mark Of 25,000 Lasers Sold In Dentistry

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

IRVINE, CA--(Marketwired - February 24, 2014) -

BIOLASE, Inc. (NASDAQ: BIOL), the world's leading manufacturer and distributor of dental lasers, including the Company's proprietary WaterLase®, and a pioneer in laser surgery in other medical specialties, as well as a distributor of digital radiography and GalaxyBioMill™ CAD/CAM systems for dentistry, today announced that it sold its 25,000th laser into the dental market last week.

Federico Pignatelli, Chairman and CEO, stated, "We are naturally very proud of this substantial milestone, one that it appears no other medical laser company has achieved in dentistry, or any other medical field, over the past 15 years. This is a clear proxy of how BIOLASE is advancing the penetration of lasers into the dental market with its best-in-class technologies, including its revolutionary WaterLase and diode lasers."

Since receiving clearance for its revolutionary WaterLase technology from the U.S. Food & Drug Administration in October 1998, BIOLASE has sold over 10,000 WaterLase and 15,000 diode lasers.

"BIOLASE has significantly expanded its product offerings in the past year to become the only Total Technology Solution™ provider in dentistry. We currently offer several variations of our flagship WaterLase system, including the revolutionary iPlus™, the WaterLase MDX™, and the MD Turbo™; two soft-tissue diode lasers, including the EPIC™ and iLase™; a number of NewTom™ 2-D and 3-D CBCT digital radiography products; several versions of Trios® intra-oral scanners; our newly introduced GALAXY BioMill chair-side milling machine; and a number of Stratasys® Design Series 3-D printers. To my knowledge, no other company currently offers such a comprehensive suite of high-tech products for dentistry," concluded Pignatelli.

About BIOLASE, Inc.
BIOLASE, Inc. is a biomedical company that develops, manufactures, and markets innovative lasers in dentistry and medicine and also markets and distributes high-end 2D and 3D digital imaging equipment, CAD/CAM intraoral scanners, and in-office milling machines and 3D printers; products that are focused on technologies that advance the practice of dentistry and medicine. The Company's proprietary laser products incorporate approximately 300 patented and patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 24,800 lasers. Other laser products under development address ophthalmology and other medical and consumer markets.

For updates and information on WaterLase and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Pinterest at www.pinterest.com/biolase, LinkedIn at www.linkedin.com/company/biolase, Google+ at www.google.com/+BIOLASEIrvine, Instagram at www.instagram.com/biolaseinc and YouTube at www.youtube.com/biolasevideos.

BIOLASE®, WaterLase®, iPlus™, MDX™, MD Turbo™, EPIC™, iLase™, GALAXY BioMill™, and Total Technology Solution™ are registered trademarks or trademarks of BIOLASE, Inc.

Trios® is a registered trademark of 3Shape A/S LLC; NewTom™ is a trademark of QR S.r.l. Corporation, a wholly-owned subsidiary of Cefla Capital Services, S.p.A.; and Stratysus® is a registered trademark of Stratasys, Inc.


For further information, please contact:
Michael Porter
Porter, LeVay & Rose, Inc.
212-564-4700

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:



Help employers find you! Check out all the jobs and post your resume.

Back to news